Docoh
Loading...

WINT Windtree Therapeutics

Windtree Therapeutics, Inc. engages in the manufacture and development of products for infants and respiratory diseases. It focuses on producing of surfactant replacement therapies for patients with respiratory disease and neonatology for the improvement of respiratory distress syndrome for infants. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Company profile

Ticker
WINT, WINTW
Exchange
CEO
Craig E. Fraser
Employees
Incorporated
Location
Fiscal year end
Former names
ANSAN INC, ANSAN PHARMACEUTICALS INC, DISCOVERY LABORATORIES INC /DE/
SEC CIK
IRS number
943171943

WINT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Mar 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 17.08M 17.08M 17.08M 17.08M 17.08M 17.08M
Cash burn (monthly) 1.76M 470.67K 2.32M 2.53M 1.51M 2.11M
Cash used (since last report) 6.27M 1.68M 8.27M 9.01M 5.39M 7.52M
Cash remaining 10.82M 15.41M 8.81M 8.08M 11.69M 9.56M
Runway (months of cash) 6.2 32.7 3.8 3.2 7.7 4.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 Apr 21 Eric Curtis Common Stock Buy Aquire P No No 2.5172 791 1.99K 1,291
6 Apr 21 Fraser Craig Common Stock Buy Aquire P No No 2.57 500 1.29K 28,298
5 Apr 21 Fraser Craig Common Stock Buy Aquire P No No 2.5799 1,000 2.58K 27,798
1 Apr 21 Fraser Craig Common Stock Buy Aquire P No No 2.4587 500 1.23K 26,798
31 Mar 21 Fraser Craig Common Stock Buy Aquire P No No 2.3199 500 1.16K 26,298

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

2.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 15 15
Opened positions 2 5 -60.0%
Closed positions 2 2
Increased positions 1 1
Reduced positions 4 1 +300.0%
13F shares
Current Prev Q Change
Total value 3.64M 4M -9.0%
Total shares 709.09K 727.33K -2.5%
Total puts 0 0
Total calls 450K 0 NEW
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 276.53K $1.42M +1.0%
Millennium Management 107.51K $552K -29.1%
Kepos Capital 90K $462K 0.0%
NTRS Northern Trust 72.39K $371K -11.3%
Frontier Wealth Management 60K $308K 0.0%
tru Independence 60K $308K NEW
Deerfield Management 20.15K $103K 0.0%
Paloma Partners Management 18.47K $95K -50.2%
Tower Research Capital 3.58K $19K NEW
UBS UBS Group AG - Registered Shares 367 $2K -82.0%
Largest transactions
Shares Bought/sold Change
tru Independence 60K +60K NEW
Millennium Management 107.51K -44.2K -29.1%
Paloma Partners Management 18.47K -18.62K -50.2%
GS Goldman Sachs 0 -10.91K EXIT
NTRS Northern Trust 72.39K -9.21K -11.3%
Tower Research Capital 3.58K +3.58K NEW
Vanguard 276.53K +2.79K +1.0%
UBS UBS Group AG - Registered Shares 367 -1.67K -82.0%
Cutler 0 -3 EXIT
WFC Wells Fargo & Co. 31 0 0.0%

Financial report summary

?
Competition
Abbvie
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: advocate, Africa, agenda, AMP, analogy, androstane, BARDA, bargaining, Baricitinib, BBA, Biden, Biomedical, Bipartisan, broaden, bulk, card, Cardiology, Carlo, ceiling, Changshu, commensurate, compelled, Congressional, contradictory, departure, dissemination, Distinguishing, donut, driven, endeavor, enrichment, EUA, Evan, exacerbated, exert, fight, filtration, fit, flux, gap, genuine, Gung, Hamill, heard, Hefei, heightened, HF, HFpEF, Hg, hole, home, hypoperfusion, hypothecate, illustrative, incentivizing, IVDR, Judge, Ladenburg, Leslie, lethal, lockup, Loh, MDR, mm, Monte, motivate, neutralizing, Oppenheimer, outlook, outreach, Overallotment, PF, PolyPeptide, presumption, problem, prompted, pure, ratably, ready, rebate, receptor, reengage, reinvest, Relief, remanded, remdesivir, reopening, repay, repayable, repayment, repealed, rescue, reward, rhythm, Robert, rural, safeguard, SciAnda, Scott, sequence, sequester, serotype, shift, solution, South, speed, stable, stimulating, subscription, syncytial, Taxpayer, Thalmann, theft, trillion, Trump, unconstitutional, underwriting, underwritten, undo, unusual, unwanted, vaccine, viral, virtual, workplace, write
Removed: accelerated, accelerating, accreted, achievable, Allergy, allocating, attached, categorized, circumvention, cisplatin, clinic, Codification, cold, Commonwealth, comprise, conserve, context, countermeasure, defer, division, Eleison, eligibility, encouraged, expressed, extinguished, Farmaceutici, feature, hereto, ILC, immaterial, incomplete, Inferior, inhaled, Joseph, Leone, lipid, Mahady, match, multiplied, NIAID, nonbinding, OTC, OTCQB, Overview, participant, powered, PRC, premise, proportionately, pursued, quotation, reader, refrigeration, restructure, retention, retired, retrospective, routinely, SBIR, SPA, Steering, Subtopic, tightly, traded, unaudited, verified, waived